Invanz lyophilizate for preparation of solution for injection in 1g vial, 1pc

Composition

bottle contains 1,213 grams of ertapenem sodium, which is equivalent to 1 gram of ertapenem as a free acid.

Inactive substances:

sodium bicarbonate – 203 mg,

sodium hydroxide up to pH 7.5.

The sodium content is approximately 137 mg (approximately 6 mEq).

Pharmacological action

Invanz has a broad-spectrum antibacterial effect.

Indications

Treatment of severe and moderate infectious and inflammatory diseases caused by sensitive strains of microorganisms (including for starting empirical antibacterial therapy before determining pathogens):

infections of the abdominal cavity;

skin and subcutaneous tissue infections, including infections of the lower extremities in diabetes mellitus (“diabetic” foot);

community-acquired pneumonia;

urinary system infections (including pyelonephritis);

acute pelvic infections (including postpartum endomyometritis, septic abortion and postoperative gynecological infections);

bacterial septicemia.

Use during pregnancy and lactation

There is no sufficient clinical experience of using Invanza during pregnancy.

Prescribing the drug is possible only in cases where the intended benefit of therapy for the mother justifies the potential risk to the fetus.

With caution, Invanz is prescribed during lactation (breastfeeding), since ertapenem is excreted in breast milk.

Contraindications

Established hypersensitivity to the components of the drug or to other antibiotics of the same group;hypersensitivity to other beta-lactam antibiotics.

When lidocaine hydrochloride is used as a solvent, intravenous use of the drug is contraindicated in patients with established hypersensitivity to local amide anesthetics, patients with severe arterial hypotension or with impaired intracardiac conduction.

Side effects

From the central nervous system: often-headache; rarely-dizziness, drowsiness, insomnia (0.2%), convulsions, confusion.

From the digestive system: often — diarrhea, nausea, vomiting; rarely-candidiasis of the oral mucosa, constipation, belching of acidic contents, pseudomembranous colitis (often manifested by diarrhea) caused by uncontrolled reproduction with Clostridium difficile, dry mouth, dyspepsia, anorexia.

From the cardiovascular system: rarely-a decrease in blood pressure.

From the respiratory system: rarely-dyspnoea. Dermatological reactions: rarely-erythema, pruritus.

On the part of the body as a whole: rarely — abdominal pain, taste distortion, weakness/fatigue, candidiasis, swelling, fever, chest pain.

Local reactions: often-postinfusion phlebitis/thrombophlebitis.

From the genitals: vaginal itching.

Interaction

When prescribing ertapenem together with drugs that block tubular secretion, no dosage adjustment is required.

Ertapenem does not affect the metabolism of xenobiotics mediated by the six main isoforms of cytochrome P450 ( CYP) – 1A2,2C9,2C19,2D6,2E1AND ZA4 (see Interaction with other drugs).

Drug interactions caused by inhibition of tubular secretion, impaired binding to P-glycoprotein, or changes in the intensity of microsomal oxidation are unlikely.

No specific clinical studies on interaction with specific drugs, other than probenecid, have been conducted.

How to take, course of use and dosage

In/in or in/m.

The average daily dose of Invanza for adults is 1 g, the frequency of use is 1 time per day.

Invanz is administered by intravenous infusion or intramuscular injection.

When administered intravenously, the duration of the infusion should be 30 minutes.

Intravenous use may be an alternative to intravenous infusion. The recommended dose is 500 mg / day.

Special instructions

Before starting treatment with Invanz, the patient should be carefully asked about previous hypersensitivity reactions to other allergens (especially penicillins, cephalosporins and other beta-lactam antibiotics).

If an allergic reaction occurs, Invanz should be discontinued immediately.

Serious anaphylactic reactions require emergency treatment.

Long-term use of Invanza, like other antibiotics, can lead to excessive growth of insensitive microorganisms.

If a superinfection develops, appropriate measures should be taken.

Form of production

Lyophilizate for solution preparation for injection

Storage conditions

At a temperature not exceeding 25 °C

Shelf life

2 years

Active ingredient

Ertapenem

Conditions of release from pharmacies

By prescription

Dosage form

solution for injection and infusion

Indications

Urinary Tract Infections, Skin Infections, Pneumonia